Bio News
Phase 3 results reported for next-generation obesity treatment retatrutide<br>Adverse-event discontinuation rate reached 11% in the highest-dose group, drawing attention to efficacy and safety

Eli Lilly’s next-generation obesity treatment retatrutide produced an average weight reduction of 28.3% after 80 weeks of treatment in a phase 3 trial. Although this approached the level seen with metabolic-bariatric surgery, the discontinuation rate due to adverse events reached 11% in the highest-dose group. In the overall analysis, which included participants who discontinued treatment, a 25% weight-reduction efficacy was confirmed.

BIOBOOK TEAM
biobookmedia@biobook.co.krAribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases